Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy
NCT06798558
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
54
Enrollment
OTHER
Sponsor class
Conditions
Prostate Adenocarcinoma
Interventions
DRUG:
Lu-17-PSMA-617
Sponsor
Hackensack Meridian Health
Collaborators
[object Object]
[object Object]